• In Mexico, cardiovascular disease remains the number one cause of death.[i]
  • It is estimated that by 2035 the incidence of coronary heart disease and stroke will increase by 40%[ii]

CARMEN BEACH Committed to continuing medical education, Amgen Mexico, a leading biotechnology company, has successfully completed the 2023 edition of the Hyperlipidemia Academy Latin America, a national and international forum in which experts in cardiovascular health gathered.

According to INEGI, during 2021 there were 1,117,0167 deaths, highlighting the cause number 1 for cardiovascular diseases, followed by complications derived from COVID-19 and diabetes mellitus[iii].

Therefore, the Academy of Hyperlipidemia was held in Playa del Carmen with the aim of updating specialists with the highest academic quality in various topics, such as initial diagnosis of a patient with hypercholesterolemia, coronary risk stratification, atherothrombosis, its genesis and causes, role of PCSK9 in intensive lipid control, reduction of LDL-C and plaque alterations, between others.

According to the World Health Organization (WHO), the high cholesterolespecially that of low density lipoproteins (LDL), also known as bad cholesterol, is the most common form of dyslipidemia, an abnormality of cholesterol and/or fat in the blood[iv]. He cholesterol It is a lipid found in the blood that the body needs to form healthy cells. However, having high levels of “bad” cholesterol (LDL-C) can increase your risk of developing cardiovascular events, which include strokes and heart attacks, so lowering your blood level is extremely important.[v].

There are different factors that can cause high levels of LDL cholesterol, such as having a diet based on saturated fat, being overweight, lack of physical activity, constant consumption of alcohol and tobacco, diseases such as chronic kidney disease (CKD), diabetes and HIV.[vi]

“Fortunately, there are different alternatives for the treatment of LDL cholesterol, such as changes in lifestyle and diet, as well as innovative treatments such as monoclonal antibodies that inhibit the protein convertase subtilisin/kexin type 9 (PCSK9), thereby dramatically and safely lowering LDL-C, the most critical risk factor for reducing cardiovascular events,” said Dr. Max Saráchaga, Chief Medical Officer for Amgen Mexico.

This edition of the Hyperlipidemia Academy ended with great success, as specialists were able to share their experiences and knowledge about cutting-edge treatments, notably that the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS, for its acronym in English ) indicate in their most recent dyslipidemia guidelines that treatment with lipid-lowering inhibitors PCSK9 it is fundamental for the prevention of cardiovascular events in very high risk patients; It should be noted that these guidelines support a considerable reduction in recommended levels of LDL cholesterol. Recommended values ​​for very high-risk patients who do not meet their goal are 50% below your baseline values ​​and the target number should be below 55mg/dL. and in high-risk patients, levels should be below 70mg/dL.[vii]

“For Amgen Mexico, one of its priorities is to continue training thousands of healthcare professionals in different therapeutic areas to expand, update and strengthen their knowledge in medical innovations that can positively impact the lives of thousands of Mexican patients, as in Academy of Hyperlipidemia. At Amgen, we will also continue to offer awareness campaigns such as cholesterol alert where they can find more information to take care of cardiovascular health, inviting them to constantly review their levels with a specialist”, said Dr. Max Saráchaga, Chief Medical Officer for Amgen Mexico.

To learn more about cholesterol alert visit: www.alertacolesterol.com and follow us on: FB Alerta Colesterol and TW @Acholesterol

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious disease by discovering, developing, manufacturing and launching innovative human treatments. This approach starts with using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of unmet medical need and leverages its expertise to find solutions that improve health outcomes, dramatically improving people’s lives. A pioneer in biotechnology since 1980, Amgen has become one of the world’s leading independent biotechnology companies, reaching millions of patients and developing a pipeline of medicines with significant potential.

Visit: https://www.amgen.com.mx and follow us on Twitter @AmgenMexico, Facebook Amgen Mexico and LinkedIn Amgen



Isa Flores / 55 2899 6716 (press relations agency)


Issath Martínez / 55 6702 7875 (public relations agency)


[i] National Institute of Geography and Statistics. INEGI. 2021. Characteristics of deaths registered in Mexico during 2021, Preliminaries. Retrieved on February 20, 2023 at: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2022/dr/dr2021_07.pdf

[ii] Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of a therapy to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease. NEVER Heart. 2017;2(10):1069-1078. Accessed February 20, 2023 at: https://pubmed.ncbi.nlm.nih.gov/28832867

[iii] National Institute of Geography and Statistics. INEGI. 2021. Characteristics of deaths registered in Mexico during 2021, Preliminaries. Retrieved on February 20, 2023 at: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2022/dr/dr2021_07.pdf

[iv] World Health Organization. Quantifying Selected Major Health Risks. In: World Health Report 2002 – Reducing Risks, Promoting Healthy Living. Chapter 4. Geneva: World Health Organization; 2002:47-97. Accessed February 20, 2023 at: https://apps.who.int/iris/bitstream/handle/10665/42510/WHR_2002.pdf

[v] Mayo Clinic. High cholesterol. Accessed February 20, 2023 at: https://www.mayoclinic.org/es-es/diseases-conditions/high-blood-cholesterol/symptoms-causes/syc-20350800

[vi] Dr. Victoria Cachofero. Cholesterol disorders and cardiovascular disease. Complutense University of Madrid. Retrieved on February 20, 2023 at: https://www.fbbva.es/microsites/salud_cardio/mult/fbbva_libroCorazon_cap13.pdf

[vii] Interamerican Society of Cardiology SIAC. European guidelines 2021 for cardiovascular prevention in clinical practice. Retrieved on February 20, 2023 at: https://www.siacardio.com/wp-content/uploads/2015/01/2-GUIA-PREVENCI%C3%93N-CV-DISLIPEMIA.pdf

AGÊNCIA EFE SA is not responsible for the information contained in this message and does not assume any responsibility towards third parties for its entire content, being also exonerated from the responsibility of the entity that authorized it.